BERKELEY HEIGHTS, N.J., Dec. 30 /PRNewswire-FirstCall/ -- Genta Incorporated announced that the Company will hold a conference call for investors to provide an update related to near-term regulatory activities for its lead anticancer compound Genasense(R) (oblimersen sodium) injection, and other upcoming Company milestones on Wednesday, January 4, 2006 at 9:00 AM ET. Raymond P. Warrell, Jr., M.D., Chairman and Chief Executive Officer will host the conference call.
The conference call can be accessed live as follows: US/Canada Dial-in: (877) 634-8606 Passcode: Genta Incorporated International Dial-In: (706) 679-3140 Passcode: Genta Incorporated Live audio webcast: http://www.genta.com/genta/InvestorRelation/events.html
Audio replay will be available approximately two hours after the completion of the call and will be archived for 30 days.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company’s research platform is anchored by two major programs that center on oligonucleotides (RNA- and DNA- based medicines) and small molecules. Genasense(R) (oblimersen sodium) Injection, the Company’s lead compound from its oligonucleotide program, is currently undergoing late-stage, Phase 3 clinical testing. The Company has filed a new drug application (NDA) to the U.S. FDA for the use of Genasense in combination with chemotherapy for the treatment of relapsed or refractory CLL. In addition, the Company has also indicated its intention to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for the use of Genasense plus dacarbazine in patients with advanced melanoma before the end of 2005. The leading drug in Genta’s small molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of patients with cancer related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: http://www.genta.com.
This press release contains forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company’s Annual Report/Form 10-K for 2004.
Genta Incorporated
CONTACT: Investor Relations, Tara Spiess of TS Communications Group, LLC,spiess@biotechirpr.com, +1-914-921-5900; or Media Relations, Greg Tiberendof Richard Lewis Communications, Inc., +1-212-827-0020
